☆ 4.5 Review

Genetics of ankylosing spondylitis

MOLECULAR IMMUNOLOGY (2014)

Journal

MOLECULAR IMMUNOLOGY

Volume 57, Issue 1, Pages 2-11

Publisher

PERGAMON-ELSEVIER SCIENCE LTD

DOI: 10.1016/j.molimm.2013.06.013

Keywords

Ankylosing spondylitis; Spondyloarthritis; Single nucleotide polymorphism association

Categories

Biochemistry & Molecular Biology Immunology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory arthritis that affects the spine and sacroiliac joints. It causes significant disability and is associated with a number of other features including peripheral arthritis, anterior uveitis, psoriasis and inflammatory bowel disease (IBD). Significant progress has been made in the genetics of AS have in the last five years, leading to new treatments in trial, and major leaps in understanding of the aetiopathogenesis of the disease. (C) 2013 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Rheumatology

Heterogeneity of axial spondyloarthritis: genetics, sex and structural damage matter

Zhixiu Li, Sjef M. van der Linden, Muhammad Asim Khan, Heinz Baumberger, Hermine van Zandwijk, Mohammad Kazim Khan, Peter M. Villiger, Matthew A. Brown

Summary: The objective of this study is to assess heterogeneity in axial spondyloarthritis (axSpA) and its sources. The results suggest that women clinically diagnosed with axSpA but without radiographic sacroiliitis have distinct characteristics compared to men with non-radiographic axSpA.

RMD OPEN (2022)

Add to Collection

Article Rheumatology

HLA-B27, axial spondyloarthritis and survival

Zhixiu Li, Mohammad Kazim Khan, Sjef M. van der Linden, Bjorn Winkens, Peter M. Villiger, Heinz Baumberger, Hermine van Zandwijk, Muhammad Asim Khan, Matthew A. Brown

Summary: This study found that patients with ankylosing spondylitis (AS) have a higher mortality rate compared to the general population, and healthy individuals carrying the HLA-B27 gene also have a similar risk. Additionally, female patients have a lower life expectancy. However, in the overall European population, the presence of the HLA-B27 gene does not affect survival or the risk of death from cardiovascular disease.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Article Rheumatology

Association between HLA-B27 and peripheral spondyloarthritis phenotype: results from the ASAS perSpA study

Marta Arevalo Salaet, Clementina Lopez-Medina, Mireia Moreno, Victoria Navarro-Compan, Joan Calvet Fontova, Maria Llop, Maxime Dougados, Jordi Gratacos

Summary: This study analyzed the influence of HLA-B27 in the phenotypical expression of pSpA. The results showed that HLA-B27-positive patients had an earlier disease onset and higher axial involvement, tarsitis, and uveitis, but no association with other EMM, fibromyalgia, or peripheral structural damage was observed.

RMD OPEN (2022)

Add to Collection

Article Immunology

Assessing the association of leukocyte telomere length with ankylosing spondylitis and rheumatoid arthritis: A bidirectional Mendelian randomization study

Donglei Wei, Yage Jiang, Jianwen Cheng, Hui Wang, Ke Sha, Jinmin Zhao

Summary: This study systematically assessed the causal relationship between leukocyte telomere length (LTL) and ankylosing spondylitis (AS) and rheumatoid arthritis (RA) using Mendelian randomization. The results suggested that longer LTL might be associated with an increased risk of developing AS.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Review Rheumatology

Axial spondyloarthritis

Victoria Navarro-Compan, Alexandre Sepriano, Bassel El-Zorkany, Desiree van der Heijde

Summary: Axial spondyloarthritis is a chronic inflammatory disease primarily affecting the axial skeleton, leading to symptoms such as chronic back pain and spinal stiffness. Diagnosis relies on recognizing clinical patterns and utilizing clinical, laboratory, and imaging features. Treatment options include non-steroidal anti-inflammatory drugs as first-line therapy, with biologics as a second-line option, showing efficacy in improving disease symptoms.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Medicine, Research & Experimental

Genome-wide association study reveals ethnicity-specific SNPs associated with ankylosing spondylitis in the Taiwanese population

Ching-Lung Ko, Wei-Zhi Lin, Meng-Ting Lee, Yu-Tien Chang, Hung-Che Lin, Yi-Syuan Wu, Jun-Fu Lin, Ke-Ting Pan, Yu-Chuan Chang, Ko-Han Lee, Yi-Lun Lee, Tsung-Ting Hsieh, Jia-Hsin Huang, Chih-Hung Wang, Sung-Sen Yang, Hsiang-Cheng Chen, Chi-Ming Chu

Summary: This study explored the race-specific SNP susceptibility of AS in Taiwanese individuals and found an association between HLA-B27 and AS susceptibility SNPs. The study also found differences in AS SNPs between Taiwanese individuals and other races, and that Taiwanese individuals with HLA-B27 positivity had a higher proportion of minor alleles. Additionally, AS polygenic risk score models were developed and individuals with high polygenic risk had a fivefold increased risk of developing AS.

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

Add to Collection

Article Rheumatology

Factors predicting axial spondyloarthritis among first-degree relatives of probands with ankylosing spondylitis: a family study spanning 35 years

Sjef M. van der Linden, Muhammad Asim Khan, Zhixiu Li, Heinz Baumberger, Hermine van Zandwijk, Kazim Khan, Peter M. Villiger, Matthew A. Brown

Summary: The occurrence of acute anterior uveitis (AAU) among first-degree relatives (FDRs) of axial spondyloarthritis (axSpA) patients should prompt screening for axSpA. The co-occurrence of chronic inflammatory back pain (CIBP) and pain/discomfort in the thoracic spine and anterior chest wall can further enhance clinical suspicion of axSpA among these FDRs.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Review Microbiology

Metabolomic analysis in spondyloarthritis: A systematic review

Tianwen Huang, Yaoyu Pu, Xiangpeng Wang, Yanhong Li, Hang Yang, Yubin Luo, Yi Liu

Summary: Spondyloarthritis (SpA) is a rheumatic disease that causes joint inflammation. Metabolomic profiling studies have provided insights into etiological factors and biomarkers for SpA.

FRONTIERS IN MICROBIOLOGY (2022)

Add to Collection

Article Rheumatology

Recurrence of axial spondyloarthritis among first-degree relatives in a prospective 35-year-follow-up family study

Sjef M. van der Linden, Muhammad Asim Khan, Zhixiu Li, Heinz Baumberger, Hermine van Zandwijk, Mohammad Kazim Khan, Peter M. Villiger, Matthew A. Brown

Summary: The lifetime recurrence risk of axSpA is substantial for HLA-B27(+) FDRs, and disease severity and the gender of the proband's children are associated with the risk of developing axSpA.

RMD OPEN (2022)

Add to Collection

Article Ophthalmology

Uveitis-related Factors in Patients With Spondyloarthritis: TReasure Real-Life Results

Nazife Sule Yasar Bilge, Umut Kalyoncu, Pamir Atagunduz, Ediz Dalkilic, Yavuz Pehlivan, Orhan Kucuksahin, Cemal Bes, Servet Akar, Muhammet Cinar, Hakan Emmungil, Duygu Ersozlu, Askin Ates, Ridvan Mercan, Gezmis Kimyon, Suleyman Serdar Koca, Emel Gonullu, Veli Yazisiz, Emre Tekgoz, Nilufer Alpay-Kanitez, Abdulsamet Erden, Sedat Kiraz, Belkis Nihan Coskun, Burcu Yagiz, Ufuk Ilgen, Omer Karadag, Levent Kilic, Ihsan Ertenli, Timucin Kasifoglu

Summary: The study aimed to analyze the frequency and factors associated with acute anterior uveitis (AAU) in different forms of Spondyloarthritis (SpA) in a large Turkish cohort. It was found that older age, smoking history, delayed diagnosis, longer disease duration, arthritis, positive HLA-B27, family history of SpA, and radiographic damage were associated with a higher prevalence of uveitis in SpA patients. Psoriasis and psoriatic arthritis patients had a lower prevalence of uveitis. Early detection of uveitis can aid in the diagnosis of SpA.

AMERICAN JOURNAL OF OPHTHALMOLOGY (2021)

Add to Collection

Article Immunology

Active Inflammatory and Chronic Structural Damages of Sacroiliac Joint in Patients With Radiographic Axial Spondyloarthritis and Non-Radiographic Axial Spondyloarthritis

Liudan Tu, Churong Lin, Ya Xie, Xiaohong Wang, Qiujing Wei, Yanli Zhang, Jieruo Gu

Summary: This study found that patients with radiographic axial spondyloarthritis (r-axSpA) showed more active inflammatory and chronic structural damages on MRI compared to non-radiographic axial spondyloarthritis (nr-axSpA) patients, especially in terms of fat metaplasia and ankylosis.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Rheumatology

Real-World Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results From the Canadian Spondyloarthritis Research Network

Robert D. Inman, Denis Choquette, Majed Khraishi, Dafna D. Gladman, Shamiza Hussein, Drew Neish, Patrick Leclerc

Summary: This study aimed to describe the real-world use of Secukinumab (SEC) in Canadian patients with axSpA. The results showed that SEC was effective in treating axSpA, with improvements in disease activity observed in patients after 12 months of treatment.

JOURNAL OF RHEUMATOLOGY (2023)

Add to Collection

Article Rheumatology

ASAS consensus definition of early axial spondyloarthritis

Victoria Navarro-Compan, Diego Benavent, Dafne Capelusnik, Desiree van der Heijde, Robert B. M. Landewe, Denis Poddubnyy, Astrid van Tubergen, Xenofon Baraliakos, Filip E. van den Bosch, Floris A. van Gaalen, Lianne Gensler, Clementina Lopez-Medina, Helena Marzo-Ortega, Anna Molto, Rodolfo Perez-Alamino, Martin Rudwaleit, Marleen van de Sande, Raj Sengupta, Ulrich Weber, Sofia Ramiro

Summary: This study developed a consensual definition for 'early axial spondyloarthritis-axSpA' and 'early peripheral spondyloarthritis-pSpA' through a systematic literature review and Delphi survey. The results indicated that early axSpA should be based on symptom duration only, without considering the presence of radiographic damage.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Review Rheumatology

Glucocorticoids in spondyloarthritis-systematic review and real-world analysis

Varun Dhir, Debasish Mishra, Joydeep Samanta

Summary: Although studies on systemic and local injections of GCs in SpA are limited, there is evidence of efficacy with high-dose systemic GCs in the short term (<= 6 months). Both IA and entheseal injections appear to be safe and effective.

RHEUMATOLOGY (2021)

Add to Collection

Article Rheumatology

Peptide-based vaccine targeting IL17A attenuates experimental spondyloarthritis in HLA-B27 transgenic rats

Hiroki Hayashi, Jiao Sun, Yuka Yanagida, Shota Yoshida, Satoshi Baba, Akiko Tenma, Masayoshi Toyoura, Sotaro Kawabata, Takako Ehara, Ryoko Asaki, Makoto Sakaguchi, Hideki Tomioka, Munehisa Shimamura, Ryuichi Morishita, Hiromi Rakugi, Tetsuya Tomita, Hironori Nakagami

Summary: This study aimed to assess the efficacy of an IL17A peptide-based vaccine on SpA manifestations in model rats. The results showed that the IL17A peptide-based vaccine successfully induced antibody production and suppressed the arthritis score and joint thickness. It also inhibited enthesitis, bone destruction, and new bone formation. The study suggests that the IL17A peptide-based vaccine may be a therapeutic option for SpA treatment.

RMD OPEN (2023)

Add to Collection

Letter Rheumatology

Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Arnaud and Devilliers

Pedro M. Machado, Martin Schaefer, Anja Strangfeld, Laure Gossec, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F. Mateus, Loreto Carmona, Kimme L. Hyrich, Philip C. Robinson, Jinoos Yazdany

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Letter Rheumatology

Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Mulhearn et al

Martin Schaefer, Anja Strangfeld, Kimme L. Hyrich, Loreto Carmona, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F. Mateus, Laure Gossec, Philip C. Robinson, Jinoos Yazdany, Pedro M. Machado

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Letter Rheumatology

Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Rosenbaum et al

Kimme L. Hyrich, Martin Schaefer, Anja Strangfeld, Loreto Carmona, Laure Gossec, Elsa F. Mateus, Saskia Lawson-Tovey, Milena Gianfrancesco, Philip C. Robinson, Jinoos Yazdany, Pedro M. Machado

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Letter Rheumatology

Response to: Correspondence on Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis by Sparks et al

Jeffrey A. Sparks, Zachary S. Wallace, Andrea M. Seet, Philip C. Robinson, Pedro M. Machado, Jinoos Yazdany

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Review Rheumatology

Examining the Characteristics of Colchicine-Induced Myelosuppression in Clinical Cases: A Systematic Review

Bernice L. Sim, Beatrice Z. Sim, Matthew Tunbridge, David F. L. Liew, Philip C. Robinson

Summary: This systematic review identified 30 studies involving 47 patients with myelosuppression caused by colchicine. Most patients had comorbidities, such as renal impairment, and were taking CYP3A4 or P-gp inhibitors. The severity of myelosuppression varied, ranging from moderate anemia to severe thrombocytopenia, neutropenia, and leukopenia.

JOURNAL OF RHEUMATOLOGY (2023)

Add to Collection

Article Rheumatology

Why Do Some Patients Have Severe Sacroiliac Disease But No Syndesmophytes in Ankylosing Spondylitis ? Data From a Nested Case-Control Study

Lauren K. Ridley, Mark C. Hwang, John D. Reveille, Lianne S. Gensler, Mariko L. Ishimori, Matthew A. Brown, Mohammad H. Rahbar, Amirali Tahanan, Michael M. Ward, Michael H. Weisman, Thomas J. Learch

Summary: This study investigated a subgroup of patients with ankylosing spondylitis (AS) who had long-standing disease and fused sacroiliac (SI) joints and found that females and males with early symptom onset had less radiographic damage in the SI joints. All 23 patients without syndesmophytes were HLA-B27 positive.

JOURNAL OF RHEUMATOLOGY (2023)

Add to Collection

Article Rheumatology

COVID-19 vaccine hesitancy in inflammatory arthritis patients: serial surveys from a large longitudinal national Australian cohort

Christopher McMaster, David F. L. Liew, Susan Lester, Adam Rischin, Rachel J. Black, Vibhasha Chand, Ashley Fletcher, Marissa N. Lassere, Lyn March, Philip C. Robinson, Rachelle Buchbinder, Catherine L. Hill

Summary: This study aimed to determine the COVID-19 vaccine hesitancy rates among inflammatory arthritis patients and identify factors associated with changing vaccine hesitancy over time. The findings showed that beliefs about medication harm and overuse before the pandemic were associated with COVID-19 vaccine hesitancy. Furthermore, individuals who did not seek vaccine information from healthcare professionals were more likely to develop vaccine hesitancy during the pandemic.

RHEUMATOLOGY (2023)

Add to Collection

Article Rheumatology

Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID-19 Global Rheumatology Alliance

Manuel F. Ugarte-Gil, Graciela S. Alarcon, Andrea M. Seet, Zara Izadi, Anna D. Montgomery, Ali Duarte-Garcia, Emily L. Gilbert, Maria O. Valenzuela-Almada, Leanna Wise, Jeffrey A. Sparks, Tiffany Y. -T. Hsu, Kristin M. D'Silva, Naomi J. Patel, Emily Sirotich, Jean W. Liew, Jonathan S. Hausmann, Paul Sufka, Rebecca Grainger, Suleman Bhana, Zachary Wallace, Lindsay Jacobsohn, Anja Strangfeld, Elsa F. Mateus, Kimme L. Hyrich, Laure Gossec, Loreto Carmona, Saskia Lawson-Tovey, Lianne Kearsley-Fleet, Martin Schaefer, Pedro M. Machado, Philip C. Robinson, Milena Gianfrancesco, Jinoos Yazdany

Summary: A study on individuals with SLE in the US found that Black and Hispanic patients had higher odds of experiencing more severe COVID-19 outcomes compared to White patients, which may be attributed to socioeconomic and health disparities.

ARTHRITIS CARE & RESEARCH (2023)

Add to Collection

Article Rheumatology

Equity Considerations in COVID-19 Vaccination Studies of Individuals With Autoimmune Inflammatory Rheumatic Diseases

Harry Wang, Omar Dewidar, Samuel L. L. Whittle, Elizabeth Ghogomu, Glen Hazlewood, Karin Leder, Lawrence Mbuagbaw, Jordi Pardo Pardo, Philip C. C. Robinson, Rachelle Buchbinder, Vivian Welch

Summary: This study examined the extent to which populations experiencing inequities were considered in studies on COVID-19 vaccination in individuals with autoimmune inflammatory rheumatic diseases (AIRDs). The results showed that sex and age were the most frequently considered factors in these studies. However, the generalizability of evidence to populations experiencing inequities is uncertain.

ARTHRITIS CARE & RESEARCH (2023)

Add to Collection

Article Medicine, General & Internal

Outcomes of COVID-19 in people with rheumatic and musculoskeletal disease in Ireland over the first 2 years of the pandemic

Richard Conway, Elena Nikiphorou, Christiana A. Demetriou, Candice Low, Kelly Leamy, John G. Ryan, Ronan Kavanagh, Alexander D. Fraser, John J. Carey, Paul O'Connell, Rachael M. Flood, Ronan H. Mullan, David J. Kane, Frances Stafford, Philip C. Robinson, Jean W. Liew, Rebecca Grainger, Geraldine M. McCarthy

Summary: This study investigated the COVID-19 outcomes for individuals with rheumatic and musculoskeletal diseases in Ireland. The results showed that increasing age, gout, smoking, long-term glucocorticoid use, comorbidities, and specific comorbidities were associated with higher rates of hospitalization and mortality.

IRISH JOURNAL OF MEDICAL SCIENCE (2023)

Add to Collection

Article Rheumatology

Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19 A Multicenter Retrospective Cohort Study

Kanon Jatuworapruk, Panchalee Satpanich, Philip C. Robinson, Rebecca Grainger

Summary: This study aimed to investigate the prevalence and outcomes of gout flare in COVID-19 hospitalized patients with comorbid gout. It was found that gout flare occurred in 18% of the hospitalized patients and added up to 3 days to the hospital length of stay.

JOURNAL OF RHEUMATOLOGY (2023)

Add to Collection

Article Multidisciplinary Sciences

Which clinical research questions are the most important? Development and preliminary validation of the Australia & New Zealand Musculoskeletal (ANZMUSC) Clinical Trials Network Research Question Importance Tool (ANZMUSC-RQIT)

William Taylor, Robin Willink, Denise A. O'Connor, Vinay L. Patel, Allison Bourne, Ian Harris, Samuel Whittle, Bethan S. Richards, Ornella G. Clavisi, Sally Green, Rana Hinman, Chris Maher, Ainslie E. Cahill, Annie McPherson, Charlotte C. Hewson, Suzie May, Bruce Walker, Philip Robinson, Davina Ghersi, Jane Fitzpatrick, Tania Winzenberg, Kieran Fallon, Paul Glasziou, Laurent Billot, Rachelle Buchbinder

Summary: The Australia and New Zealand Musculoskeletal (ANZMUSC) Clinical Trials Network developed a Research Question Importance Tool (ANZMUSC-RQIT) to rank research projects based on their importance. The tool consists of 5 dimensions and is designed for scoring by committee consensus.

PLOS ONE (2023)

Add to Collection

Article Public, Environmental & Occupational Health

Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors

Victor Yang, Tue W. Kragstrup, Christopher McMaster, Pankti Reid, Namrata Singh, Stine R. Haysen, Philip C. Robinson, David F. L. Liew

Summary: Janus kinase inhibitors (JAKi) have shown great potential as immune-modulating therapies for chronic inflammatory diseases. However, concerns about cardiovascular and cancer risks have arisen from recent studies, particularly in patients with rheumatoid arthritis and existing cardiovascular risk. While this risk has not been fully demonstrated in other patient populations, it has led to a re-evaluation of the use of JAKi in various contexts. Clinicians must carefully consider these risks and other factors when considering JAKi as a treatment option for their patients.

DRUG SAFETY (2023)

Add to Collection

Article Rheumatology

Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries

Pedro M. Machado, Martin Schaefer, Satveer K. Mahil, Jean Liew, Laure Gossec, Nick Dand, Alexander Pfeil, Anja Strangfeld, Anne Constanze Regierer, Bruno Fautrel, Carla Gimena Alonso, Carla G. S. Saad, Christopher E. M. Griffiths, Claudia Lomater, Corinne Miceli-Richard, Daniel Wendling, Deshire Alpizar Rodriguez, Dieter Wiek, Elsa F. Mateus, Emily Sirotich, Enrique R. Soriano, Francinne Machado Ribeiro, Felipe Omura, Frederico Rajao Martins, Helena Santos, Jonathan Dau, Jonathan N. Barker, Jonathan Hausmann, Kimme L. Hyrich, Lianne Gensler, Ligia Silva, Lindsay Jacobsohn, Loreto Carmona, Marcelo M. Pinheiro, Marcos David Zelaya, Maria de los Angeles Severina, Mark Yates, Maureen Dubreuil, Monique Gore-Massy, Nicoletta Romeo, Nigil Haroon, Paul Sufka, Rebecca Grainger, Rebecca Hasseli, Saskia Lawson-Tovey, Suleman Bhana, Thao Pham, Tor Olofsson, Wilson Bautista-Molano, Zachary S. Wallace, Zenas Z. N. Yiu, Jinoos Yazdany, Philip C. Robinson, Catherine H. Smith

Summary: This study investigated factors associated with severe COVID-19 in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis. The study found that age, sex, comorbidities, disease activity, and glucocorticoid use were associated with the severity of COVID-19. Additionally, later pandemic time periods, psoriasis, and the use of TNFi, IL17i, and IL-23i/IL-12+23i were associated with a reduced risk of severe COVID-19.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Letter Rheumatology

Response to: Correspondence on Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis by Sparks et al

Zachary S. Wallace, Jeffrey A. Sparks, Philip C. Robinson, Pedro M. Machado, Jinoos Yazdany

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.